Oncology News

Molecules in saliva may be highly sensitive and specific noninvasive biomarkers of hepatocellular carcinoma, according to a study published in PeerJ.

Lenvatinib plus transarterial chemoembolization prolonged survival and improved response rates among patients in China with advanced hepatocellular carcinoma, according to study results presented at ASCO Gastrointestinal Cancers Symposium.

The FDA granted orphan drug designation to silmitasertib for treatment of biliary tract cancer.

The benefit of immune checkpoint inhibitor therapy for hepatocellular carcinoma did not vary by underlying liver disease, according to study results presented at ASCO Gastrointestinal Cancers Symposium.

Adjuvant S-1 therapy significantly extended survival compared with surgery alone among patients with resected biliary tract cancer, according to results of a study conducted in Japan and presented at ASCO Gastrointestinal Cancers Symposium.

Use of beta blockers did not affect outcomes among patients treated with immunotherapy for unresectable hepatocellular carcinoma, according to study results presented at ASCO Gastrointestinal Cancers Symposium.

Pembrolizumab conferred a small but statistically significant survival benefit when added to best supportive care as second-line treatment for patients with advanced hepatocellular carcinoma, according to a phase 3 study conducted in Asia.

Neoadjuvant immunotherapy Libtayo administered before surgical resection led to tumor necrosis in about one-third of patients with hepatocellular carcinoma, according to data published in The Lancet Gastroenterology and Hepatology.

Among patients newly diagnosed with hepatocellular carcinoma, there are significant racial and ethnic differences in barriers to care, according to survey results published in Clinical Gastroenterology and Hepatology.

The CDC’s Advisory Committee on Immunization Practices recently issued a universal recommendation that all adults aged 19 to 59 years receive the hepatitis B vaccine.